SCHEMBL13712

SCHEMBL13712

NC(=O)Nc1ccccc1OC(F)(F)F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.55
ALDH1A1 P00352 3/20 0.49
EPHX2 P34913 1/20 0.48
ATR Q13535 1/20 0.47
ANO1 Q5XXA6 5/20 0.45
NAMPT P43490 1/20 0.45
PDK1 Q15118 1/20 0.45
PDK2 Q15119 1/20 0.45
PDK3 Q15120 1/20 0.45
PDK4 Q16654 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
KIT P10721 1/20 0.45
KDR P35968 1/20 0.45
FLT3 P36888 1/20 0.45
KDM4E B2RXH2 1/20 0.44
P2RY1 P47900 1/20 0.44
IDH2 P48735 1/20 0.44
KCNK3 O14649 1/20 0.43
KCNK9 Q9NPC2 1/20 0.43
MLYCD O95822 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30140662 0.88 GAA (0.51) GAAALDH1A1EPHX2ATRANO1
SCHEMBL2095941 0.86 GAA (0.55) GAAEPHX2ATRANO1NAMPT
SCHEMBL2095943 0.86 GAA (0.55) GAAEPHX2ATRANO1NAMPT
SCHEMBL5643498 0.85 GAA (0.55) GAAALDH1A1EPHX2ATRANO1
SCHEMBL30142030 0.84 L3MBTL1 (0.49) GAAALDH1A1EPHX2ATRANO1
SCHEMBL5521725 0.84 L3MBTL1 (0.49) GAAALDH1A1EPHX2ATRANO1
SCHEMBL16291113 0.84 GAA (0.54) GAAALDH1A1EPHX2NAMPTKDM4E
SCHEMBL5962103 0.84 POLB (0.56) GAAALDH1A1EPHX2PDK1PDK2
SCHEMBL8084614 0.84 GAA (0.57) GAAEPHX2ATRANO1NAMPT
SCHEMBL9474879 0.83 ADRA2C (0.61) GAAALDH1A1EPHX2ATRNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611806-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Ascepion Pharmaceuticals, Inc. (CN) 2013-07-10 EP claimed
WO-2012028106-A1 DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ASCEPION PHARMACEUTICALS, INC. (CN) 2012-03-08 WO claimed
EP-1581217-A4 CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS MERCK & CO INC (US) 2007-07-11 EP claimed
EP-1581217-A1 CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2005-10-05 EP claimed
EP-1521583-A1 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO (2,1-B)-QUINAZOLINONE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2005-04-13 EP claimed
WO-2004041277-A1 CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2004-05-21 WO claimed
WO-2004004733-A1 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO[2,1-B]-QUINAZOLINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2004-01-15 WO claimed
WO-2020193448-A1 MULTITARGET COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE UNIVERSITAT DE BARCELONA (ES) 2020-10-01 WO disclosed
CN-104540831-B The difluoro dioxolanes aminobenzimidazole kinase inhibitor disorderly for treating cancer, autoimmune inflammation and CNS 4SC探索有限责任公司 2017-11-07 CN disclosed
EP-1539766-B1 CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2016-12-21 EP disclosed
CN-104540831-A Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders 4SC DISCOVERY GMBH 2015-04-22 CN disclosed
CN-103110951-A Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective rtk inhibitors ALCON INC 2013-05-22 CN disclosed
CN-102417487-A Indazole, benzisoxazole and benzisothiazole kinase inhibitors ABBOTT LAB 2012-04-18 CN disclosed
CN-1787996-A Nitrogen-containing heterocyclic derivative and drug containing the same as active ingredient ONO PHARMACEUTICAL CO (JP) 2006-06-14 CN disclosed
EP-1638941-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-03-29 EP disclosed
EP-1581217-A1 CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2005-10-05 EP disclosed
EP-1521583-A1 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO (2,1-B)-QUINAZOLINONE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2005-04-13 EP disclosed
WO-2004113304-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-12-29 WO disclosed
WO-2004041277-A1 CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2004-05-21 WO disclosed
WO-2004004733-A1 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO[2,1-B]-QUINAZOLINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2004-01-15 WO disclosed